Purchase this article with an account.
Juliet A Moncaster, Rajendra K Gangalum, Olga Minaeva, John C Voss, Dean Hartley, Suraj P Bhat, Carmela Abraham, Bertrand R Huber, Patric K Stanton, Lee E Goldstein; aB-Crystallin expression in Alzheimer’s Disease brain in neuritic and diffuse plaques. Invest. Ophthalmol. Vis. Sci. 2016;57(12):730.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Alzheimer’s disease plaques in the brain are composed of amyloid-β (Aβ) and also contain low molecular weight chaperones including αB-crystallin. We investigated where αB-crystallin is expressed particularly in neuritic versus diffuse plaques and how this may impact AD pathology through interaction with Aβ.
Immunohistofluorescence, confocal microscopy, immunogold electron microscopy, SDS-page and immunoblotting, spectral reflectance imaging biosensor, electrophysiology, cell and organotypic slice culture.
Immunohistochemical analysis of human Alzheimer’s disease brain revealed co-localization of human Aβ and human αB-crystallin in neuritic and diffuse plaques. Immunohistochemistry and immunoblotting analysis demonstrated that the αB-crystallin is expressed and secreted from astrocytes in close proximity to the plaques and affects Aβ fibrillogenesis and neurotoxcicity.
Our data show that αB-crystallin is expressed in Alzheimer’s Disease human brain in neuritic and diffuse plaques and interacts with Aβ. Our results indicate that αB-crystallin plays an antagonistic pleiotropy role that may be critical to the pathogenesis of Alzheimer’s disease.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only